StockInvestor editor Paul Larson details recent changes to Morningstar's Wide Moat Focus Index, noting how the rally in wide-moat names could have them more fairly priced than lower-quality stocks.
Recent rebalancing of Morningstar's Wide Moat Focus Index shows that quality stocks aren't nearly as cheap as they were this time last year.
Competitive advantages improved for one health-care firm, while a spin-off at another narrowed its moat, says Morningstar's Paul Larson in his discussion on recent moat-rating upgrades and downgrades.
These three exemplary managers have widened their firms' economic moats and created real value for shareholders over the years.
As negative headlines continue to roll in, a market upswing suggests investors are expecting more stimulus action from the Fed.
We don't know what the end game in Europe is yet, but these firms should be able to withstand the flood, says Morningstar's Paul Larson and Dave Sekera.
Morningstar's Paul Larson breaks down the five ways firms can keep competitors at bay and which ways are more durable over time.
Morningstar's Heather Brilliant details our 10-year track record for stocks, particularly the strong outperformance of 5-star names with competitive advantages.
Morningstar StockInvestor editor Matt Coffina offers some of his new investment ideas following a quarterly rebalancing of the Wide Moat Focus Index.
Morningstar StockInvestor editor Matt Coffina discusses recent additions to the Wide Moat Focus Index.
Morningstar StockInvestor editor Matt Coffina explains why he recently purchased Novo Nordisk for StockInvestor's real-money Hare portfolio.
Morningstar StockInvestor editor Matt Coffina explains why a fairly valued stock should outperform both cash and bonds over the long run.
©2012 Morningstar Advisor. All right reserved.